Terms: = Colorectal cancer AND KRAS, C-K-RAS, 3845, P01116, NS3, KI-RAS, KRAS2, K-RAS4A, K-RAS2A, K-RAS4B, KRAS1, K-RAS2B, RASK2 AND Treatment
2465 results:
1. Genomic Alterations and Clinical Characterization in Chinese Patients with Metastatic colorectal cancer.
Zhang XH; Zhou JQ; Wei Q; Li J; Xu T; Bai CM; Zhou JF; Wang XC
Discov Med; 2024 Jul; 36(186):1477-1485. PubMed ID: 39054718
[TBL] [Abstract] [Full Text] [Related]
2. Cribriform morular thyroid carcinoma: Clinicopathological and molecular basis for both a preventive and therapeutic approach for a rare tumor (Review).
Cameselle-García S; Abdulkader-Nallib I; Sánchez-Ares M; Cameselle-Teijeiro JM
Oncol Rep; 2024 Sep; 52(3):. PubMed ID: 39027989
[TBL] [Abstract] [Full Text] [Related]
3. Clinical features associated with NeoRAS wild-type metastatic colorectal cancer A SCRUM-Japan GOZILA substudy.
Osumi H; Shinozaki E; Nakamura Y; Esaki T; Yasui H; Taniguchi H; Satake H; Sunakawa Y; Komatsu Y; Kagawa Y; Denda T; Shiozawa M; Satoh T; Nishina T; Goto M; Takahashi N; Kato T; Bando H; Yamaguchi K; Yoshino T
Nat Commun; 2024 Jul; 15(1):5885. PubMed ID: 39003289
[TBL] [Abstract] [Full Text] [Related]
4. Epidermal Growth Factor Receptor Targeting in colorectal Carcinoma: Antibodies and Patient-Derived Organoids as a Smart Model to Study Therapy Resistance.
Tardito S; Matis S; Zocchi MR; Benelli R; Poggi A
Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000238
[TBL] [Abstract] [Full Text] [Related]
5. Current and Emerging treatment Paradigms in colorectal cancer: Integrating Hallmarks of cancer.
Salva de Torres C; Baraibar I; Saoudi González N; Ros J; Salva F; Rodríguez-Castells M; Alcaraz A; García A; Tabernero J; Élez E
Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000083
[TBL] [Abstract] [Full Text] [Related]
6. Dual inhibition of SUMOylation and MEK conquers MYC-expressing kras-mutant cancers by accumulating DNA damage.
Kotani H; Oshima H; Boucher JC; Yamano T; Sakaguchi H; Sato S; Fukuda K; Nishiyama A; Yamashita K; Ohtsubo K; Takeuchi S; Nishiuchi T; Oshima M; Davila ML; Yano S
J Biomed Sci; 2024 Jul; 31(1):68. PubMed ID: 38992694
[TBL] [Abstract] [Full Text] [Related]
7. Novel drug resistance mechanisms and drug targets in BRAF-mutated peritoneal metastasis from colorectal cancer.
Lund-Andersen C; Torgunrud A; Kanduri C; Dagenborg VJ; Frøysnes IS; Larsen MM; Davidson B; Larsen SG; Flatmark K
J Transl Med; 2024 Jul; 22(1):646. PubMed ID: 38982444
[TBL] [Abstract] [Full Text] [Related]
8. Biomarker Testing Disparities in Metastatic colorectal cancer.
Sabbagh S; Herrán M; Hijazi A; Jabbal IS; Mohanna M; Dominguez B; Itani M; Sarna K; Liang H; Nahleh Z; Wexner SD; Nagarajan A
JAMA Netw Open; 2024 Jul; 7(7):e2419142. PubMed ID: 38967928
[TBL] [Abstract] [Full Text] [Related]
9. Selective PI3Kδ inhibitor TYM-3-98 suppresses AKT/mTOR/SREBP1-mediated lipogenesis and promotes ferroptosis in kras-mutant colorectal cancer.
Zheng YN; Lou SY; Lu J; Zheng FL; Tang YM; Zhang EJ; Cui SL; Zhao HJ
Cell Death Dis; 2024 Jul; 15(7):474. PubMed ID: 38956060
[TBL] [Abstract] [Full Text] [Related]
10. Regorafenib synergizes with TAS102 against multiple gastrointestinal cancers and overcomes cancer stemness, trifluridine-induced angiogenesis, ERK1/2 and STAT3 signaling regardless of kras or BRAF mutational status.
Zhang J; Zhou L; Zhao S; El-Deiry WS
Oncotarget; 2024 Jul; 15():424-438. PubMed ID: 38953895
[TBL] [Abstract] [Full Text] [Related]
11. krasFormer: a fully vision transformer-based framework for predicting
Singh VK; Makhlouf Y; Sarker MMK; Craig S; Baena J; Greene C; Mason L; James JA; Salto-Tellez M; O'Reilly P; Maxwell P
Biomed Phys Eng Express; 2024 Jul; 10(5):. PubMed ID: 38925106
[TBL] [Abstract] [Full Text] [Related]
12. Multifaceted effects of LRP6 in cancer: exploring tumor development, immune modulation and targeted therapies.
Li L; Zhao L; Yang J; Zhou L
Med Oncol; 2024 Jun; 41(7):180. PubMed ID: 38898247
[TBL] [Abstract] [Full Text] [Related]
13. Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis.
Cohen R; Raeisi M; Chibaudel B; Shi Q; Yoshino T; Zalcberg JR; Adams R; Cremolini C; Van Cutsem E; Heinemann V; Tabernero J; Punt CJA; Arnold D; Hurwitz HI; Douillard JY; Venook AP; Saltz LB; Maughan TS; Kabbinavar F; Bokemeyer C; Grothey A; Mayer RJ; Kaplan R; Tebbutt NC; Randolph Hecht J; Giantonio BJ; Díaz-Rubio E; Sobrero AF; Peeters M; Koopman M; Goldberg RM; Andre T; de Gramont A
Eur J Cancer; 2024 Aug; 207():114160. PubMed ID: 38896997
[TBL] [Abstract] [Full Text] [Related]
14. Impact of Oncogenic Changes in p53 and kras on Macropinocytosis and Ferroptosis in Colon cancer Cells and Anticancer Efficacy of Niclosamide with Differential Effects on These Two Processes.
Nguyen NT; Sennoune SR; Dharmalingam-Nandagopal G; Sivaprakasam S; Bhutia YD; Ganapathy V
Cells; 2024 May; 13(11):. PubMed ID: 38891084
[TBL] [Abstract] [Full Text] [Related]
15. To explore the prognostic characteristics of colon cancer based on tertiary lymphoid structure-related genes and reveal the characteristics of tumor microenvironment and drug prediction.
Wang Z; Niu D
Sci Rep; 2024 Jun; 14(1):13555. PubMed ID: 38867070
[TBL] [Abstract] [Full Text] [Related]
16. MYG1 drives glycolysis and colorectal cancer development through nuclear-mitochondrial collaboration.
Chen J; Duan S; Wang Y; Ling Y; Hou X; Zhang S; Liu X; Long X; Lan J; Zhou M; Xu H; Zheng H; Zhou J
Nat Commun; 2024 Jun; 15(1):4969. PubMed ID: 38862489
[TBL] [Abstract] [Full Text] [Related]
17. Comparison of genomic profiling of patient-matched primary colorectal and surgical resected distant metastatic (stage IV) colorectal carcinoma for drug actionability.
Jan YH; Lu CT; Lam AK
Hum Pathol; 2024 Jul; 149():21-28. PubMed ID: 38862093
[TBL] [Abstract] [Full Text] [Related]
18. Unlocking the potential of flavonoids: Natural solutions in the fight against colon cancer.
Hasibuan PAZ; Simanjuntak Y; Hey-Hawkins E; Lubis MF; Rohani AS; Park MN; Kim B; Syahputra RA
Biomed Pharmacother; 2024 Jul; 176():116827. PubMed ID: 38850646
[TBL] [Abstract] [Full Text] [Related]
19. Plasma ctDNA enhances the tissue-based detection of oncodriver mutations in colorectal cancer.
Wang W; Huang Y; Kong J; Lu L; Liao Q; Zhu J; Wang T; Yan L; Dai M; Chen Z; You J
Clin Transl Oncol; 2024 Aug; 26(8):1976-1987. PubMed ID: 38777950
[TBL] [Abstract] [Full Text] [Related]
20. Epidermal growth factor receptor antagonists in colorectal cancer: emerging strategies for precision therapy.
González NS; Marchese PV; Baraibar I; Ros J; Salvà F; Rodríguez M; Salvà C; Vaghi C; Alcaraz A; García A; Tabernero J; Élez E
Expert Opin Investig Drugs; 2024 Jun; 33(6):613-625. PubMed ID: 38775361
[TBL] [Abstract] [Full Text] [Related]
[Next]
